£300bn AstraZeneca-BMS Merger Faces Antitrust Firestorm Under Trump
The proposed mega-merger would immediately trigger intense antitrust reviews in the US, EU, and UK, testing the limits of Trump-era competition enforcement in the pharmaceutical sector. Significant divestitures and political pushback are likely, with a real risk of deal collapse.